Sheena C Kerr1, Jeanmarie R Gonzalez2,3, Julia Schanin4, Michael C Peters1, Bart N Lambrecht5, Emily C Brock4, Annabelle Charbit1, K M Ansel2,3, Bradford A Youngblood4, John V Fahy1,3. 1. Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, CA, USA. 2. Department of Microbiology and Immunology, University of California, San Francisco, CA, USA. 3. Sandler Asthma Basic Research Center, University of California, San Francisco, CA, USA. 4. Allakos. Inc, Redwood City, CA, USA. 5. VIB Center for Inflammation Research, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Abstract
BACKGROUND: Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is expressed on mast cells and eosinophils, but information about Siglec-8 expression and function in the lung is limited. A humanized antibody, AK002, targeting Siglec-8 is undergoing development for treatment of diseases associated with mast cell and eosinophil-driven inflammation. OBJECTIVE: To characterize Siglec-8 expression in the airway in asthma and determine whether antibodies that target Siglec-8 (S8mAbs) can decrease airway eosinophils in asthma or inhibit lung mast cell activation. METHODS: Gene expression profiling and flow cytometry were used to characterize Siglec-8 expression in sputum cells from stable asthma. An antibody-dependent cellular cytotoxicity (ADCC) assay was used to determine whether an S8mAb can decrease eosinophils in sputum from asthma patients ex vivo. A mast cell activation assay was used to determine whether an S8mAb can inhibit mast cell activation in human lung tissue ex vivo. RESULTS: Gene expression for Siglec-8 is increased in sputum cells in asthma and correlates with gene expression for eosinophils and mast cells. Gene expression for Siglec-8 is inversely and significantly correlated with measures of airflow obstruction in asthma patients. Siglec-8 is prominently expressed on the surface of eosinophils and mast cells in sputum. S8mAbs decrease eosinophils in sputum from patients with asthma and inhibit FcεR1-activated mast cells in lung tissues. CONCLUSIONS AND CLINICAL RELEVANCE: Siglec-8 is highly expressed on eosinophils and mast cells in asthmatic sputum and targeting Siglec-8 with an antibody is a plausible strategy to decrease sputum eosinophils and inhibit lung mast cells in asthma.
BACKGROUND:Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is expressed on mast cells and eosinophils, but information about Siglec-8 expression and function in the lung is limited. A humanized antibody, AK002, targeting Siglec-8 is undergoing development for treatment of diseases associated with mast cell and eosinophil-driven inflammation. OBJECTIVE: To characterize Siglec-8 expression in the airway in asthma and determine whether antibodies that target Siglec-8 (S8mAbs) can decrease airway eosinophils in asthma or inhibit lung mast cell activation. METHODS: Gene expression profiling and flow cytometry were used to characterize Siglec-8 expression in sputum cells from stable asthma. An antibody-dependent cellular cytotoxicity (ADCC) assay was used to determine whether an S8mAb can decrease eosinophils in sputum from asthmapatients ex vivo. A mast cell activation assay was used to determine whether an S8mAb can inhibit mast cell activation in human lung tissue ex vivo. RESULTS: Gene expression for Siglec-8 is increased in sputum cells in asthma and correlates with gene expression for eosinophils and mast cells. Gene expression for Siglec-8 is inversely and significantly correlated with measures of airflow obstruction in asthmapatients. Siglec-8 is prominently expressed on the surface of eosinophils and mast cells in sputum. S8mAbs decrease eosinophils in sputum from patients with asthma and inhibit FcεR1-activated mast cells in lung tissues. CONCLUSIONS AND CLINICAL RELEVANCE: Siglec-8 is highly expressed on eosinophils and mast cells in asthmatic sputum and targeting Siglec-8 with an antibody is a plausible strategy to decrease sputum eosinophils and inhibit lung mast cells in asthma.
Authors: Bradford A Youngblood; Emily C Brock; John Leung; Rustom Falahati; Bruce S Bochner; Henrik S Rasmussen; Kathryn Peterson; Christopher Bebbington; Nenad Tomasevic Journal: JCI Insight Date: 2019-10-03
Authors: Bradford A Youngblood; Emily C Brock; John Leung; Rustom Falahati; Paul J Bryce; Jessica Bright; Jason Williams; Leonard D Shultz; Dale L Greiner; Michael A Brehm; Christopher Bebbington; Nenad Tomasevic Journal: Int Arch Allergy Immunol Date: 2019-08-09 Impact factor: 2.749
Authors: Mats W Johansson; Elizabeth A Kelly; Christopher L Nguyen; Nizar N Jarjour; Bruce S Bochner Journal: Int Arch Allergy Immunol Date: 2018-06-07 Impact factor: 2.749
Authors: Michael C Peters; Zesemayat K Mekonnen; Shaopeng Yuan; Nirav R Bhakta; Prescott G Woodruff; John V Fahy Journal: J Allergy Clin Immunol Date: 2013-09-24 Impact factor: 10.793
Authors: Anh L Innes; Stephen D Carrington; David J Thornton; Sara Kirkham; Karine Rousseau; Ryan H Dougherty; Wilfred W Raymond; George H Caughey; Susan J Muller; John V Fahy Journal: Am J Respir Crit Care Med Date: 2009-05-07 Impact factor: 21.405
Authors: Michael C Peters; Lando Ringel; Nathan Dyjack; Rachelle Herrin; Prescott G Woodruff; Cydney Rios; Brian O'Connor; John V Fahy; Max A Seibold Journal: Am J Respir Crit Care Med Date: 2019-02-15 Impact factor: 30.528
Authors: Pavel Kolkhir; Daniel Elieh-Ali-Komi; Martin Metz; Frank Siebenhaar; Marcus Maurer Journal: Nat Rev Immunol Date: 2021-10-05 Impact factor: 53.106
Authors: Bradford A Youngblood; John Leung; Rustom Falahati; Jason Williams; Julia Schanin; Emily C Brock; Bhupinder Singh; Alan T Chang; Jeremy A O'Sullivan; Robert P Schleimer; Nenad Tomasevic; Christopher R Bebbington; Bruce S Bochner Journal: Cells Date: 2020-12-24 Impact factor: 6.600
Authors: Anabel Gonzalez-Gil; T August Li; Ryan N Porell; Steve M Fernandes; Haley E Tarbox; Hyun Sil Lee; Kazuhiro Aoki; Michael Tiemeyer; Jean Kim; Ronald L Schnaar Journal: J Allergy Clin Immunol Date: 2020-08-11 Impact factor: 10.793